Evidence map›Paper›PMID 24560108›Full record

ArticleSurgical oncology clinics of North America2014

Intrahepatic cholangiocarcinoma.

Kimberly M Brown, Abhishek D Parmar, David A Geller

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  7. Review
  8. mTranslational oncology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Diagnosis of Cholangiocarcinoma.Diagnostics (Basel, Switzerland) · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kimberly M BrownDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0541, USA. Electronic address: km3brown@utmb.edu.
Abhishek D ParmarDepartment of Surgery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0541, USA; Department of Surgery, University of California San Francisco-East Bay, 1411 East 31st Street, Oakland, CA 94602, USA.
David A GellerLiver Cancer Center, University of Pittsburgh School of Medicine, 3459 Fifth Avenue, Pittsburgh, PA 15213-2582, USA. Electronic address: gellerda@upmc.edu.
The University of Texas Medical Branch at Galveston · USUPMC Hillman Cancer Center · US

Funding

UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
SURGICAL TRAINING IN GASTROINTESTINAL ENDOCRINOLOGYT32DK007639 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI RADHAKRISHNAN, RAVI S. · 1992 to 2022
$3.6M
NCATS NIH HHS UL1 TR000071NCATS NIH HHS UL1TR000071NIDDK NIH HHS 5T32DK007639NIDDK NIH HHS T32 DK007639
6 · The paper itself

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare tumor, with an increasing incidence worldwide and an overall poor prognosis. Symptoms are usually nonspecific, contributing to an advanced tumor stage at diagnosis. The staging system for ICC has recently been updated and is based on number of lesions, vascular invasion, and lymph node involvement. Complete surgical resection to negative margins remains the only potentially curable treatment for ICC. Gemcitabine-based adjuvant therapy can be offered based on limited data from patients with unresectable ICC. Overall 5-year survivals after resection range from 17% to 44%, with median survivals of 19 to 43 months.

Indexed as

Bile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaHumansBile duct neoplasmsCholangiocarcinomaIntrahepatic bile duct cancerIntrahepatic cholangiocarcinomaPeripheral cholangiocarcinoma

Identifiers

PMID24560108
PMCPMC4007210
OpenAlexW4238989635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.